Deal for PROPENSITY4 grows company’s data analytics knowledge
Ashfield Engage, part of UDG Healthcare plc, has purchased PROPENSITY4, an integrated data and insight solutions provider serving the pharma and biotech industry. The acquisition follows multiple years of partnership; in fact, Ashfield invested in PROPENSITY4 back in 2021.
The deal—according to Ashfield—is expected to further the company’s capability in applying analytical knowledge to existing data to redesign programs which increase return on investment across commercial, patient engagement and medical affairs services, and improve patient outcomes.
“Ashfield Engage works across the pharmaceutical industry, including top 20 pharma and emerging biotech, to establish and maintain exceptional relationships with the various healthcare stakeholders throughout the commercialization journey,” says Christopher Savage, the firm’s global head of strategy. “Our customer engagement expertise—combined with the unparalleled data analytics we have gained through the acquisition of PROPENSITY4—will allow us to supersize our offering, ensuring we’re delivering the right message to the right customer at the right time in the right channel to maximize impact.”